[New combination chemotherapy for malignant melanoma--PAV(peplomycin, ACNU, VCR) therapy].
A combination chemotherapy (PAV) consisting of peplomycin, ACNU and vincristine (VCR) was given to 30 patients with malignant melanoma and its therapeutic evaluation was performed. The objective response rate was 42.9% for the patients with stage IV metastatic lesions; three of 7 patients showed improvement. This regimen was particularly effective for both cutaneous and subcutaneous metastatic lesions. When PAV was applied as an adjuvant therapy to the operable cases with stage Ib and II, a five-year survival rate was 50% and the result was far better than that of operation alone. Our results in PAV regimen almost identical with those of DAV(DTIC, ACNU, and VCR) regimen as an adjuvant therapy. The result indicates that PAV regimen is useful for the treatment of malignant melanoma since toxic reactions were mild. Further studies are necessary to assess the efficacy of PAV regimen.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D015376:Nimustine; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D017663:Peplomycin; D012878:Skin Neoplasms / Q000188:drug therapy*; D014750:Vincristine / Q000627:therapeutic use
D009607:Nitrosourea Compounds; D015376:Nimustine; D001761:Bleomycin; D017663:Peplomycin; D014750:Vincristine